Hematological oncology
Hematol Oncol
· ISSN (e) 1099-1069
· 1 paper in corpus
observational
2022
Ruxolitinib is a safe and effective therapy of myeloproliferative neoplasm-associated (MPN) myelofibrosis. However, often there are dose reductions and/or therapy interruptions because of therapy-related adverse events (AEs), especially ane…